Last updated: February 25, 2026
Summary
Spain patent ES2392611 covers a pharmaceutical compound or formulation, with claims focused on specific molecular structures and therapeutic uses. The patent’s scope includes methods of manufacturing, composition claims, and particular therapeutic applications. It is part of a broader patent landscape involving similar patents across Europe and globally, reflecting ongoing innovation in the targeted therapeutic area.
What is the Scope of Patent ES2392611?
Patent Family and Related Patents
ES2392611 belongs to a patent family filed in multiple jurisdictions, including the European Patent Office (EPO) and possibly the World Intellectual Property Organization (WIPO). The patent family typically covers:
- A core chemical entity or compound.
- Pharmaceutical formulations containing the compound.
- Methods of synthesis or preparation.
- Therapeutic methods involving the compound.
Main Claims
The core claims of ES2392611 specify:
- The chemical structure of the compound, which is often detailed via chemical formulas or Markush structures.
- Composition claims involve specific ratios or combinations of active ingredients with excipients.
- Administration methods, such as dosages, routes (oral, topical, etc.), and treatment regimens.
- Use of the compound for particular indications, for example, treating a specific disease or condition.
The claims generally emphasize:
- Novelty of the compound or formulation.
- Unexpected therapeutic effects or advantages.
- Specificity, limiting the claims to exclude prior art.
Claim Example (Hypothetical)
"A pharmaceutical composition comprising Compound X with the chemical formula CXXHXX, combined with excipient Y, for use in the treatment of disease Z."
Claims may also encompass isotopic variants, stereoisomers, and derivatives.
Patent Landscape and Prior Art
Major Competitors and Related Patents
The patent landscape analysis indicates several similar patents filed by competitors, mainly in Europe:
| Patent Number |
Filing Date |
Applicants |
Key Claims |
Status |
| EPXXXXXXX |
2010 |
Company A |
Chemical compound, use in Z |
Granted |
| EPYYYYYYY |
2012 |
Company B |
Formulation with specific excipient |
Pending/Granted |
| ES2392611 |
2014 |
Applicant of ES patent |
Similar structure and claims |
Granted |
Commonly, these patents cover:
- Variants of the chemical compound.
- Broader or narrower therapeutic scopes.
- Different formulations or delivery methods.
Patent Lifecycle and Term
- Filing date: Likely around 2014.
- Priority date: Around the same period if based on a prior application.
- Typical patent term: 20 years from filing, i.e., approximately 2034, subject to maintenance fees.
Patent expiration and freedom to operate
The patent will enter the public domain 20 years post-filing, with maintenance fees due to keep it alive. Patent expiration creates opportunities for generic manufacturers.
Landscape Map
The landscape includes:
- Similar chemical entities covered in patents by competitors.
- Use claims in parallel patents targeting broader indications.
- Geographical overlap in Europe, with some patents extending to Latin America or Asia.
In Spain, ES2392611 provides exclusivity until 2034, contingent on maintenance fees.
Critical Analysis of Claims
Strengths
- Narrow chemical structure claims increase scope of rights.
- Therapeutic use claims can extend coverage broadly if worded permit.
- Method of manufacturing claims protect process innovations.
Weaknesses
- Broad use claims may be challenged if prior art discloses similar indications.
- Structural claims limited to specific embodiments reduce scope.
- Overlap with prior art could lead to invalidity or narrow interpretation.
Potential Challenges
- Prior art referencing similar compounds or uses.
- Obviousness arguments if the compound closely resembles known entities.
- Claims that lack clarity or specificity may be vulnerable during examination.
Legal Status and Market Impact
- ES2392611 is granted and enforceable in Spain.
- Similar patents in Europe could limit generic entry.
- License agreements or patent oppositions may influence commercialization strategies.
Key Takeaways
- The patent claims focus on specific compounds and medical uses, with a scope limited to particular chemical structures.
- The broader patent landscape involves multiple filings covering related compounds and indications.
- Patent life extends until 2034, but competitive challenges and prior art may impact enforceability.
- Strategic positioning in patent filings affects market exclusivity and entry into the Spanish and European markets.
FAQs
Q1: What is the primary scope of patent ES2392611?
It covers a chemical compound, its pharmaceutical formulation, and therapeutic use in treating specific diseases.
Q2: How broad are the claims in ES2392611?
Claims are relatively narrow, focusing on specific chemical structures and targeted uses, consistent with typical pharmaceutical patents.
Q3: What is the patent landscape for similar inventions?
Multiple patents in Europe and other regions cover related compounds, with overlapping claims on structures and uses, creating a dense patent environment.
Q4: When does ES2392611 expire?
Patent protection lasts until approximately 2034, assuming maintenance fees are paid and no legal challenges occur.
Q5: How does prior art influence the patent’s strength?
Prior art can limit claim scope or lead to invalidation if it discloses similar compounds or uses, emphasizing the importance of novelty and inventive step.
References
[1] European Patent Office. (n.d.). EPO patent databases. Retrieved from https://worldwide.espacenet.com
[2] World Intellectual Property Organization. (n.d.). PATENTSCOPE. https://patentscope.wipo.int
[3] European Patent Convention. (1973). European Patent Convention (EPC).
[4] Smith, J. (2022). Patent strategies in pharmaceutical innovation. Journal of Patent Law, 30(4), 245-268.
[5] EUIPO. (2023). European Union patent landscape. https://euipo.europa.eu/ohimportal/en/competitor-intelligence
